Prix CanSino Biologics Inc. (06185.HK)

CanSino Biologics Inc is a CN-based company operating in Biotechnology industry. The company is headquartered in Tianjin, Tianjin and currently employs 1,105 full-time employees. The company went IPO on 2019-03-28. CanSino Biologics Inc is a China-based company primarily engaged in the research and development, production, and commercialization of human vaccine products. The Company’s products and product pipeline under research include multiple vaccine varieties such as meningitis, pneumonia, diphtheria, tetanus, and pertussis (DPT), coronavirus disease 2019 (COVID-19), Ebola virus disease, poliomyelitis, herpes zoster, tuberculosis and others. The firm is also engaged in the research and development of pharmaceutical production processes. The firm conducts its business in the domestic and overseas markets.